Paediatric Exclusivity Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Paediatric Exclusivity

Health Care Term

Pediatric exclusivity refers to a regulatory incentive provided by the U.S. Food and Drug Administration (FDA) to drug manufacturers for conducting clinical trials in pediatric populations. This incentive encourages manufacturers to invest in the development and testing of drugs specifically designed for use in children. Through this program, drug manufacturers can receive an additional six months of market exclusivity, which means that no other company can market a generic version of the drug during that time.

Pediatric exclusivity was established in 1997 under the Food and Drug Administration Modernization Act (FDAMA), and it was later amended by the Best Pharmaceuticals for Children Act (BPCA) in 2002 and the Pediatric Research Equity Act (PREA) in 2003. These laws require manufacturers to conduct pediatric clinical trials for certain drugs and provide data on the safety and efficacy of those drugs in children before they can be approved for use.

The use of pediatric exclusivity in the healthcare industry has had several benefits. By incentivizing drug manufacturers to conduct clinical trials in pediatric populations, it has led to the development of new treatments and therapies specifically designed for children. This has helped to improve the health outcomes for pediatric patients and has contributed to the overall advancement of pediatric medicine.

In addition, the program has also provided financial benefits to drug manufacturers, as the additional exclusivity period can result in increased revenue from the sale of the drug. This can help to offset the costs associated with researching and developing new treatments.

Overall, pediatric exclusivity has been a valuable tool in promoting the development and testing of drugs specifically designed for use in children, and it has played an important role in advancing pediatric healthcare.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P